HRS9531 explained

HRS9531 is an experimental GLP-1 and GIPR dual agonist developed by Jiangsu Hengrui.[1] [2] [3]

Notes and References

  1. Goldenberg . Ronald M. . Gilbert . Jeremy D. . Manjoo . Priya . Pedersen . Sue D. . Woo . Vincent C. . Lovshin . Julie A. . Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists . Obesity Reviews . 15 November 2023 . 25 . 3 . e13663 . 10.1111/obr.13663. 37968541 .
  2. Goldenberg . Ronald M. . Teoh . Hwee . Verma . Subodh . Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data . Current Opinion in Cardiology . November 2023 . 38 . 6 . 539–545 . 10.1097/HCO.0000000000001084. 37792556 .
  3. He . Kun . Wei . Fang . Chen . Hong . Zhang . Yanyan . Sheng . Zhen . Wen . Qing . 763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study . Diabetes . 20 June 2023 . 72 . Supplement_1 . 10.2337/db23-763-P.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "HRS9531".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.